Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A.

J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.

PMID:
12488482
2.

Parenteral busulfan: is therapeutic monitoring still warranted?

Grochow LB.

Biol Blood Marrow Transplant. 2002;8(9):465-7. No abstract available.

3.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB.

Clin Cancer Res. 2002 Apr;8(4):963-70.

4.

Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans.

Azuma R, Saeki M, Yamamoto Y, Hagiwara Y, Grochow LB, Donehower RC.

Xenobiotica. 2002 Jan;32(1):63-72.

PMID:
11820510
5.

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.

Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB.

Cancer Chemother Pharmacol. 2001 Oct;48(4):269-74.

PMID:
11710626
6.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC.

Clin Cancer Res. 2001 Oct;7(10):3047-55.

7.

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB.

Clin Cancer Res. 2001 Aug;7(8):2330-9.

8.

Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.

Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium.

J Clin Oncol. 2001 Jul 1;19(13):3260-6.

PMID:
11432894
9.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.

PMID:
11072167
10.

A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.

Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.

Clin Cancer Res. 2000 Oct;6(10):3885-94.

11.

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

Dees EC, O'Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, Grochow LB, Donehower RC, Fetting JH.

Cancer Invest. 2000;18(6):521-9.

PMID:
10923100
12.

Population pharmacokinetic model for topotecan derived from phase I clinical trials.

Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD.

J Clin Oncol. 2000 Jun;18(12):2459-67.

PMID:
10856106
13.

Clinical potential of matrix metalloprotease inhibitors in cancer therapy.

Heath EI, Grochow LB.

Drugs. 2000 May;59(5):1043-55. Review.

PMID:
10852638
14.

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.

Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK.

J Clin Oncol. 2000 Feb;18(4):915-26.

PMID:
10673535
15.

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ.

Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46.

PMID:
10421536
16.

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C.

Ann Oncol. 1999 Mar;10(3):339-44.

PMID:
10355580
17.

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Dugan M, Cutler D, Batra V, Grochow LB, Donehower RC, Rowinsky EK.

Clin Cancer Res. 1999 Feb;5(2):309-17.

18.

Should pancreaticoduodenectomy be performed in octogenarians?

Sohn TA, Yeo CJ, Cameron JL, Lillemoe KD, Talamini MA, Hruban RH, Sauter PK, Coleman J, Ord SE, Grochow LB, Abrams RA, Pitt HA.

J Gastrointest Surg. 1998 May-Jun;2(3):207-16.

PMID:
9841976
19.

Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.

Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S.

Cancer Chemother Pharmacol. 1998;42(2):118-26.

PMID:
9654111
20.

A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.

O'Reilly S, Baker SD, Sartorius S, Rowinsky EK, Finizio M, Lubiniecki GM, Grochow LB, Gray JE, Pieniaszek HJ Jr, Donehower RC.

Ann Oncol. 1998 Jan;9(1):101-4.

PMID:
9541690
21.

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.

Kennedy MJ, Zahurak ML, Donehower RC, Noe D, Grochow LB, Sartorius S, Chen TL, Bowling K, Duerr M, Rowinsky EK.

Clin Cancer Res. 1998 Feb;4(2):349-56.

22.

High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.

Rowinsky EK, Baker SD, Burks K, O'Reilly S, Donehower RC, Grochow LB.

Ann Oncol. 1998 Feb;9(2):173-80.

PMID:
9553662
23.

Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan.

O'Reilly S, Armstrong DK, Grochow LB.

Gynecol Oncol. 1997 Dec;67(3):329-30. No abstract available.

PMID:
9441785
24.

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.

Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA.

Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60.

25.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH.

Clin Cancer Res. 1997 May;3(5):761-70.

26.

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL.

Ann Surg. 1997 May;225(5):621-33; discussion 633-6.

27.

Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.

O'Reilly S, Grochow LB, Donehower RC, Chen TL, Bowling K, Hartman NR, Struck RF, Rowinsky EK.

J Clin Oncol. 1997 May;15(5):1974-84.

PMID:
9164209
29.

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC.

Clin Cancer Res. 1997 Mar;3(3):401-7.

30.

An overview of the clinical pharmacology of topotecan.

Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ.

Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18. Review.

PMID:
9122737
31.

Pharmacology of cancer chemotherapy in the older person.

Baker SD, Grochow LB.

Clin Geriatr Med. 1997 Feb;13(1):169-83. Review.

PMID:
8995106
32.

Factors affecting topotecan sensitivity in human leukemia samples.

Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC, Rowinsky EK.

Ann N Y Acad Sci. 1996 Dec 13;803:128-42. Review. No abstract available.

PMID:
8993506
33.

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK.

J Clin Oncol. 1996 Dec;14(12):3085-96.

PMID:
8955653
34.

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.

J Clin Oncol. 1996 Dec;14(12):3074-84.

PMID:
8955652
35.

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB.

J Clin Oncol. 1996 Dec;14(12):3062-73.

PMID:
8955651
36.

Phase II Trial of Paclitaxel in Patients with Advanced Colon Cancer Previously Untreated with Cytotoxic Chemotherapy: An Eastern Cooperative Oncology Group Trial (PA286).

Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'Dwyer PJ, Petrelli NJ.

Am J Ther. 1996 Nov;3(11):750-754.

PMID:
11862233
37.

Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.

Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM.

Clin Cancer Res. 1996 Sep;2(9):1481-7.

38.

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.

O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB.

J Natl Cancer Inst. 1996 Jun 19;88(12):817-24.

PMID:
8637048
39.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK.

J Natl Cancer Inst. 1996 Jun 5;88(11):734-41.

PMID:
8637027
40.

A phase II trial of topotecan in patients with previously untreated pancreatic cancer.

O'Reilly S, Donehower RC, Rowinsky EK, Ord S, Grochow LB.

Anticancer Drugs. 1996 Jun;7(4):410-4.

PMID:
8826609
41.

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.

J Clin Oncol. 1996 Apr;14(4):1224-35.

PMID:
8648378
42.

Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.

Carducci MA, Abrams RA, Yeo CJ, Hruban RH, Zahurak ML, Cameron JL, Grochow LB.

Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):143-50.

PMID:
8641911
43.

Pharmacology of bone marrow transplantation conditioning regimens.

Jones RJ, Grochow LB.

Ann N Y Acad Sci. 1995 Dec 29;770:237-41. Review. No abstract available.

PMID:
8597364
44.

Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head.

Abrams RA, Grochow LB.

Surg Clin North Am. 1995 Oct;75(5):925-38. Review.

PMID:
7660255
45.

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC.

J Clin Oncol. 1995 Aug;13(8):1975-84.

PMID:
7636538
46.

Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood.

Anderson LW, Ludeman SM, Colvin OM, Grochow LB, Strong JM.

J Chromatogr B Biomed Appl. 1995 May 19;667(2):247-57.

PMID:
7663697
47.

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE.

J Clin Oncol. 1995 May;13(5):1136-43.

PMID:
7738619
48.

Should anticancer drug doses be adjusted in the obese patient?

Baker SD, Grochow LB, Donehower RC.

J Natl Cancer Inst. 1995 Mar 1;87(5):333-4. No abstract available.

PMID:
7853411
49.

Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.

Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB.

Cancer Res. 1995 Feb 15;55(4):810-6. Erratum in: Cancer Res 1995 Apr 1;55(7):1600.

50.

Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.

Larson RA, Geller RB, Janisch L, Milton J, Grochow LB, Ratain MJ.

Cancer Chemother Pharmacol. 1995;36(3):204-10.

PMID:
7781139

Supplemental Content

Loading ...
Support Center